Topical JAK inhibitor - An effective treatment for facial vitiligo
First alopecia treatment for autoimmune disorder that causes sudden hair loss approved by the FDA
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach | Nature Reviews Rheumatology
The Impact of JAK Inhibitors in AD Treatment
Jakinibs for Rheumatoid Arthritis Treatment
The Potential of JAK/STAT Pathway Inhibition as a New Treatment Strategy to Control Cytokine Release Syndrome in COVID-19 | Biological and Medicinal Chemistry | ChemRxiv | Cambridge Open Engage
Rheumatoid arthritis | JAK inhibitors: The next generation of drugs for treating rheumatoid arthritis? | rheumatology.medicinematters.com
FDA approves new therapy for people living with skin-discoloration disorder vitiligo - ABC News
Oral surveillance and JAK inhibitor safety: the theory of relativity | Nature Reviews Rheumatology
Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus | Annals of the Rheumatic Diseases
The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours | British Journal of Cancer
Alopecia areata treatment: a role involving Janus Kinase (JAK) inhibitors
Pharmacologic inhibition of JAK-STAT signaling promotes hair growth | Science Advances
Frontiers | Emerging Topical and Systemic JAK Inhibitors in Dermatology
Pharmacologic inhibition of JAK-STAT signaling promotes hair growth | Science Advances
JAK Inhibitors for Eczema Treatment | Gladskin
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases - ScienceDirect
New Drug Helps Some Bald Patients Regrow Hair - The New York Times
Strong Commitment' Made to JAK Inhibitor Hair Loss Treatment Development
Dermatology Risks Are Likely Different for JAK Inhibitors
JAK Inhibitor Therapy in a Child with Inherited USP18 Deficiency | NEJM
JAK inhibitors for the treatment of autoimmune and inflammatory diseases - ScienceDirect
JAK Inhibitors Are Coming and They Are the Biggest Eczema Development in Years | National Eczema Association
Frontiers | Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
Targeting the JAK-STAT pathway in the treatment of 'Th2-high' severe asthma | Future Medicinal Chemistry
The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19 - ScienceDirect
